Håkan Mellstedt

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: CANCERS. 2024;16(22):3821
A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL)
Zhong W; Kokhaei P; Mulder TA; Ghaderi A; Moshfegh A; Lundin J; Palma M; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: JOURNAL OF HEMATOLOGY. 2023;12(4):170-175
Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia
Andersson M; Wu J; Wullimann D; Gao Y; Aberg M; Muschiol S; Healy K; Naud S; Bogdanovic G; Palma M; Mellstedt H; Chen P; Ljunggren H-G; Hansson L; Chen MS; Buggert M; Ingelman-Sundberg HM; Osterborg A
Article: PHARMACEUTICS. 2023;15(4):1148
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells
Ghaderi A; Okhovat M-A; Lehto J; De Petris L; Doulabi EM; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: PHARMACEUTICS. 2022;14(10):2238
A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
Ghaderi A; Zhong W; Okhovat MA; Aschan J; Svensson A; Sander B; Schultz J; Olin T; Osterborg A; Hojjat-Farsangi M; Mellstedt H
Article: EJHAEM. 2021;2(3):525-529
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia
Lundin J; Mulder TA; Kattstrom M; Wasterlid T; Uddevik A; Mellstedt H; Heimersson K; Hansson L; Palma M; Osterborg A
Article: EJHAEM. 2021;2(3):498-502
A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1⁺ CLL cells
Ghaderi A; Okhovat M-A; Wikanthi LSS; Svensson A; Palma M; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: CELL DEATH AND DISEASE. 2021;12(6):577
Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung
Wang WZ; Shilo K; Amann JM; Shulman A; Hojjat-Farsangi M; Mellstedt H; Schultz J; Croce CM; Carbone DP
Article: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. 2021;269:75-99
Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.
Hojjat-Farsangi M; Moshfegh A; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H
Article: BIOMEDICINES. 2020;8(6):E170-170
ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells
Ghaderi A; Daneshmanesh AH; Moshfegh A; Kokhaei P; Vagberg J; Schultz J; Olin T; Harrysson S; Smedby KE; Drakos E; Rassidakis GZ; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES. 2020;23(6):800-809
Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia
Esmaili MA; Kazemi A; Faranoush M; Mellstedt H; Zaker F; Safa M; Mehrvar N; Rezvany MR
Article: LEUKEMIA. 2018;32(10):2291-2295
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells
Hojjat-Farsangi M; Daneshmanesh AH; Khan AS; Shetye J; Mozaffari F; Kharaziha P; Rathje L-S; Kokhaei P; Hansson L; Vagberg J; Bystrom S; Olsson E; Lofberg C; Norstrom C; Schultz J; Norin M; Olin T; Osterborg A; Mellstedt H; Moshfegh A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;101(1):68-77
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients
Palma M; Hansson L; Mulder TA; Adamson L; Nasman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Osterborg A; Mellstedt H
Article: PLOS ONE. 2018;13(6):e0198038
A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vagberga J; Bystrom S; Olsson E; Olin T; Osterborg A; Mellstedt H
Article: PLOS ONE. 2018;13(2):e0192839
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
Kokhaei P; Hojjat-Farsangi M; Mozaffari F; Moshfegh A; Pak F; Rashidy-Pour A; Palma M; Hansson L; Osterborg A; Mellstedt H
Article: HAEMATOLOGICA. 2017;102(3):562-572
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
Palma M; Gentilcore G; Heimersson K; Mozaffari F; Nasman-Glaser B; Young E; Rosenquist R; Hansson L; Osterborg A; Mellstedt H
Article: PLOS ONE. 2017;12(1):e0169736
Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
Ullenhag GJ; Mozaffari F; Broberg M; Mellstedt H; Liljefors M
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2017;66(1):91-102
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
Winqvist M; Mozaffari F; Palma M; Sylvan SE; Hansson L; Mellstedt H; Osterborg A; Lundin J
Article: ONCOLOGY LETTERS. 2016;12(4):2782-2788
Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions
Hogfeldt T; Jaing C; Mc Loughlin K; Thissen J; Gardner S; Bahnassy AA; Gharizadeh B; Lundahl J; Osterborg A; Porwit A; Zekri A-RN; Khaled HM; Mellstedt H; Moshfegh A
Article: TUMOR BIOLOGY. 2016;37(9):11947-11957
Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia
Khan AS; Hojjat-Farsangi M; Daneshmanesh AH; Hansson L; Kokhaei P; Osterborg A; Mellstedt H; Moshfegh A
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2015;45(6):1783-1793
Dendritic cell regulation of NK-cell responses involves lymphotoxin-, IL-12, and TGF-
Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Osterborg A; Lundqvist A
Article: PLOS ONE. 2015;10(11):e0142310
Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2014;10(11):3394-3408
Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study
Rossmann E; Osterborg A; Lofvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schroeder A; Mellstedt H
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2014;45(3):1293-1303
Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients
Staff C; Mozaffari F; Frodin J-E; Mellstedt H; Liljefors M
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2014;10(7):1828-1835
Awareness and understanding of cancer immunotherapy in Europe
Mellstedt H; Gaudernack G; Gerritsen WR; Huber C; Melero I; Parmiani G; Scholl S; Thatcher N; Wagstaff J; Zielinski C
Article: JOURNAL OF GYNECOLOGIC ONCOLOGY. 2014;25(3):221-228
Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
Woopen H; Pietzner K; Richter R; Fotopoulou C; Joens T; Braicu EI; Mellstedt H; Mahner S; Lindhofer H; Darb-Esfahani S; Denkert C; Sehouli J
Article: LEUKEMIA AND LYMPHOMA. 2014;55(5):1158-1165
Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas
Hoegfeldt T; Johnsson P; Grander D; Bahnassy AA; Porwit A; Eid S; Osterborg A; Zekri A-RN; Lundahl J; Khaled MH; Mellstedt H; Moshfegh A
Article: EJC SUPPLEMENTS. 2013;11(3):1-11
Clinical considerations for biosimilar antibodies.
Mellstedt H
Article: ANNALS OF ONCOLOGY. 2013;24:v23-v28
Anti-neoplastic biosimilars-the same rules as for cytotoxic generics cannot be applied
Mellstedt H
Article: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2013;2(1):23
Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cells.
Mikaelsson E; Osterborg A; Tahmasebi Fard Z; Mahmoudi A; Mahmoudian J; Jeddi-Tehrani M; Akhondi M; Shokri F; Bishop PN; Rabbani H; Mellstedt H
Article: EXPERIMENTAL HEMATOLOGY. 2013;41(7):615-626
Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia
Palma M; Parker A; Hojjat-Farsangi M; Forster J; Kokhaei P; Hansson L; Osterborg A; Mellstedt H
Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2013;23(5):797-802
Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer
Pietzner K; Woopen H; Richter R; Joens T; Braicu EI; Dimitrova D; Mellstedt H; Darb-Esfahani S; Denkert C; Lindhofer H; Fotopoulou C; Sehouli J
Article: LEUKEMIA AND LYMPHOMA. 2013;54(5):996-1003
Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures
Hogfeldt T; Bahnassy AA; Kwiecinska A; Osterborg A; Tamm KP; Porwit A; Zekri A-RN; Lundahl J; Khaled HM; Mellstedt H; Moshfegh A
Article: LEUKEMIA AND LYMPHOMA. 2013;54(4):843-850
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grander D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Osterborg A
Article: PLOS ONE. 2013;8(10):e78339
The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.
Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
Article: PLOS ONE. 2013;8(6):e67601
A Proline/Arginine-Rich End Leucine-Rich Repeat Protein (PRELP) Variant Is Uniquely Expressed in Chronic Lymphocytic Leukemia Cells
Mikaelsson E; Osterborg A; Jeddi-Tehrani M; Kokhaei P; Ostadkarampour M; Hadavi R; Gholamin M; Akhondi M; Shokri F; Rabbani H; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2013;62(1):51-63
T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile
Kiaii S; Kokhaei P; Mozaffari F; Rossmann E; Pak F; Moshfegh A; Palma M; Hansson L; Mashayekhi K; Hojjat-Farsangi M; Osterborg A; Choudhury A; Mellstedt H
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2012;32(4):855-865
Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein
Staff C; Magnusson CGM; Hojjat-Farsangi M; Mosolits S; Liljefors M; Frodin J-E; Wahren B; Mellstedt H; Ullenhag GJ
Article: LEUKEMIA. 2012;26(6):1348-1355
Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells
Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi A-R; Hadavi R; Osterborg A; Shokri F; Rabbani H; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2012;61(6):865-879
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
Palma M; Hansson L; Choudhury A; Nasman-Glaser B; Eriksson I; Adamson L; Rossmann E; Widen K; Horvath R; Kokhaei P; Vertuani S; Mellstedt H; Osterborg A
Article: BLOOD. 2011;117(20):5463-5472
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
Bagnara D; Kaufman MS; Calissano C; Marsilio S; Patten PEM; Simone R; Chum P; Yan X-J; Allen SL; Kolitz JE; Baskar S; Rader C; Mellstedt H; Rabbani H; Lee A; Gregersen PK; Rai KR; Chiorazzi N
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2011;38(4):1075-1081
Gene expression analysis using long-term preserved formalin-fixed and paraffin-embedded tissue of non-small cell lung cancer
Jacobson TAS; Lundahl J; Mellstedt H; Moshfegh A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2010;151(4):327-335
Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells
Choudhury A; Derkow K; Daneshmanesh AH; Mikaelsson E; Kiaii S; Kokhaei P; Osterborg A; Mellstedt H
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2010;37(6):1599-1606
FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment
Wang B; Kokhaei P; Mellstedt H; Liljefors M
Article: MINERVA CHIRURGICA. 2009;64(6):643-653
Cancer vaccines for non-small-cell lung cancer
Palma M; Choudhury A; Mellstedt H
Article: CANCER SCIENCE. 2009;100(12):2346-2353
Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia
Hojjat-Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Mellstedt H; Shokri F; Rabbani H
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2009;69(6):529-536
Generation of a Dendritic Cell-based Vaccine in Chronic Lymphocytic Leukaemia Using CliniMACS Platform for Large-scale Production
Adamson L; Palma M; Choudhury A; Eriksson I; Nasman-Glaser B; Hansson M; Hansson L; Kokhaei P; Osterborg A; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2009;58(1):111-120
Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
Mozaffari F; Lindemalm C; Choudhury A; Granstam-Bjorneklett H; Lekander M; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: INTERNATIONAL JOURNAL OF CANCER. 2008;123(5):1190-1195
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
DaneshManesh AH; Mikaelsson E; Jeddi-Tehrani M; Bayat AA; Ghods R; Ostadkarampour M; Akhondi M; Lagercrantz S; Larsson C; Osterborg A; Shokri F; Mellstedt H; Rabbani H
Article: AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY. 2008;60(2):160-171
Repertoire and clonality of T-cell receptor beta variable genes expressed in endometrium and blood T cells of patients with recurrent spontaneous abortion
Dokouhaki P; Moghaddam R; Rezvany M; Ghassemi J; Novin MG; Zarnani A; Akhondi M-M; Ostadkarampour M; Mellstedt H; Razavi A; Jeddi-Tehrani M
Article: LEUKEMIA AND LYMPHOMA. 2008;49(7):1360-1367
Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia
Shabani M; Asgarian-Omran H; Vossough P; Sharifian RA; Faranoush M; Ghragozlou S; Khoshnoodi J; Roohi A; Jeddi-Tehrani M; Mellstedt H; Rabbani H; Shokri F
Article: ANNALS OF ONCOLOGY. 2008;19(6):1172-1179
Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)
Abdalla AO; Kokhaei P; Hansson L; Mellstedt H; Osterborg A
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2008;57(3):379-388
Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity
Liljefors M; Nilsson B; Mellstedt H; Mellstedt H; Frodin J-E
Article: CLINICAL LUNG CANCER. 2008;9:S37-S44
The future of cancer vaccines for non-small-cell lung cancer: Ongoing trials
Choudhury A; Palma M; Mellstedt H
Article: SUPPORTIVE CARE IN CANCER. 2008;16(1):57-65
Immune response, depression and fatigue in relation to support intervention in mammary cancer patients
Lindemalm C; Mozaffari F; Choudhury A; Granstam-Bjorneklett H; Lekander M; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY. 2007;72B(6):450-457
Performance of calibration standards for antigen quantitation with flow cytometry chronic lymphocytic leukemia
Rossmann ED; Lenkei R; Lundin J; Mellstedt H; Oesterborg A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2007;79(5):371-381
Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients
Abdalla AO; Hansson L; Eriksson I; Nasman-Glaser B; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF CANCER. 2007;97(1):105-111
NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy
Mozaffari F; Lindemalm C; Choudhury A; Granstam-Bjorneklett H; Helander I; Lekander M; Mikaelsson E; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2007;66(1):43-51
Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer
Hallermalm K; Johansson S; Brave A; Ek M; Engstrom G; Boberg A; Gudmundsdotter L; Blomberg P; Mellstedt H; Stout R; Liu MA; Wahren B
Article: CLINICAL CANCER RESEARCH. 2007;13(12):3536-3544
Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies
Kokhaei P; Abdalla AO; Hansson L; Mikaelsson E; Kubbies M; Haselbeck A; Jernberg-Wiklund H; Mellstedt H; Osterborg A
Article: IRANIAN BIOMEDICAL JOURNAL. 2007;11(2):125-129
Analysis of HLA-G gene expression in B-lymphocytes from chronic lymphocytic leukemia patients.
Rezvany MR; Kazemi A; Hajifathali A; Kaviani S; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 2007;13(5):1503-1510
Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients
Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Article: EXPERIMENTAL HEMATOLOGY. 2007;35(2):297-304
Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Article: TUMOR BIOLOGY. 2007;28(6):318-326
Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia
Shabani M; Omran HA; Jeddi-Tehrani M; Vossough P; Faranoush M; Sharifian RA; Toughe GR; Kordmahin M; Khoshnoodi J; Roohi A; Tavoosi N; Mellstedt H; Rabbani H; Shokri F
Article: HAEMATOLOGICA. 2007;92(1):110-114
Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma -: evaluation of T-cell responses by different read-out systems
Abdalla AO; Hansson L; Eriksson I; Nasman-Glaser B; Rossmann ED; Rabbani H; Mellstedt H; Osterborg A
Article: ANNALS OF ONCOLOGY. 2007;18:i14-i21
Clinical signs and symptoms at diagnosis and its differential diagnosis
Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;135(4):475-485
Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Article: LEUKEMIA AND LYMPHOMA. 2006;47(7):1229-1238
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia:: long-term effects of fludarabine and alemtuzumab treatment
Kiaii S; Choudhury A; Mozaffari F; Rezvany R; Lundin J; Mellstedt H; Osterborg A
Article: EUROPEAN RESPIRATORY JOURNAL. 2006;27(3):451-459
Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis
Idali F; Wikén M; Wahlström J; Mellstedt H; Eklund A; Rabbani H; Grunewald J
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2006;55(2):210-220
T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil
Mellstedt H; Choudhury A
Article: CYTOTHERAPY. 2006;8(4):318-326
Generation of DC-based vaccine for therapy of B-CLL patients.: Comparison of two methods for enriching monocytic precursors
Kokhaei P; Adamson L; Palma M; Osterborg A; Pisa P; Choudhury A; Mellstedt H
Article: MEDICAL ONCOLOGY. 2006;23(2):273-282
Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells
Mahdian R; Kokhaei P; Najar HM; Derkow K; Choudhury A; Mellstedt H
Article: ONKOLOGIE. 2005;28 Suppl 4:4-8
[Active immunotherapy in patients with hematologic and solid neoplasms].
Mellstedt H; Veelken H
Article: BLOOD. 2005;105(12):4828-4835
Fibromodulin, an extracellular matrix protein:: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma
Mikaelsson E; Danesh-Manesh AH; Lüppert A; Jeddi-Tehrani M; Rezvany MR; Sharifian RA; Safaie R; Roohi A; Österborg A; Shokri F; Mellstedt H; Rabbani H
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2005;26(6):1581-1589
Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2005;54(6):557-570
T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody
Mosolits S; Markovic K; Fagerberg J; Frödin JE; Rezvany MR; Kiaii S; Mellstedt H; Jeddi-Tehrani M
Article: IMMUNOLOGY. 2005;114(3):428-437
Exposure to mercuric chloride during the induction phase and after the onset of collagen-induced arthritis enhances immune/autoimmune responses and exacerbates the disease in DBA/1 mice
Hansson M; Djerbi M; Rabbani H; Mellstedt H; Gharibdoost F; Hassan M; DePierre JW; Abedi-Valugerdi M
Article: MEDICAL ONCOLOGY. 2005;22(3):291-302
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL) comparison of indolent and progressive disease
Kiaii S; Choudhury A; Mozaffari F; Kimby E; Österborg A; Mellstedt M
Article: INTERNATIONAL JOURNAL OF CANCER. 2004;112(4):669-677
Targeting human EP-CAM in transgenic mice by anti-idiotype and antigen based vaccines
Mosolits S; Campbell F; Litvinov SV; Fagerberg J; Crowe JS; Mellstedt H; Ellis JH
Article: LEUKEMIA. 2004;18(11):1810-1815
Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL
Kokhaei P; Choudhury A; Mahdian R; Lundin J; Moshfegh A; Österborg A; Mellstedt H
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 2004;42(11):5394-5396
Association between a high BK virus load in urine samples of patients with graft-versus-host disease and development of hemorrhagic cystitis after hematopoietic stem cell transplantation
Bogdanovic G; Priftakis P; Giraud G; Kuzniar M; Ferraldeschi R; Kokhaei P; Mellstedt H; Remberger M; Ljungman P; Winiarski J; Dalianis T
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2004;25(3):703-711
Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with α-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma
Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
Article: BLOOD. 2004;104(4):948-955
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
Hale G; Rebello P; Brettman LR; Fegan C; Kennedy B; Kimby E; Leach M; Lundin J; Mellstedt H; Moreton P; Rawstron AC; Waldmann H; Osterborg A; Hillmen P
Article: CLINICAL CANCER RESEARCH. 2004;10(16):5391-5402
Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients
Mosolits S; Markovic K; Frödin JE; Virving L; Magnusson CGM; Steinitz M; Fagerberg J; Mellstedt H
Article: ANTICANCER RESEARCH. 2004;24(4):2375-2383
Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients
Shetye JD; Liljefors ML; Emdin SO; Frödin JE; Strigård K; Mellstedt HT; Porwit A
Article: CLINICAL CANCER RESEARCH. 2004;10(10):3273-3281
Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor
Ullenhag GJ; Frödin JE; Jeddi-Tehrani M; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2004;53(4):331-337
Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA
Ullenhag GJ; Fagerberg J; Strigård K; Frödin JE; Mellstedt H
Article: LEUKEMIA. 2004;18(3):484-490
Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Österborg A; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;124(3):315-324
Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage
Mozaffari F; Hansson L; Kiaii S; Ju XL; Rossmann ED; Rabbani H; Mellstedt H; Österborg A
Article: CYTOTHERAPY. 2004;6(4):363-371
Development of a technology platform for large-scale clinical grade production of DC
Adamson L; Palmborg A; Svensson A; Lundqvist A; Hansson M; Kiessling R; Masucci G; Mellstedt H; Pisa P
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2003;58(6):601-606
Kinetics of cytokine gene expression in human CD4⁺ and CD8⁺ T-lymphocyte subsets using quantitative real-time PCR
Abdalla AO; Kiaii S; Hansson L; Rossmann ED; Jeddi-Tehrani M; Shokri F; Österborg A; Mellstedt H; Rabbani H
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2003;104(2):351-358
Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy
Wadhwa M; Bird C; Fagerberg J; GainesDas R; Ragnhammar P; Mellstedt H; Thorpe R
Article: INTERNATIONAL JOURNAL OF CANCER. 2003;105(5):717-723
Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A
Liljefors M; Nilsson B; Skog ALH; Ragnhammar P; Mellstedt H; Frödin JE
Article: CLINICAL CANCER RESEARCH. 2003;9(7):2447-2456
Immunization of colorectal carcinoma patients with a recombinant Canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colonystimulating factor induced a tumor-specific cellular immune response
Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
Article: BLOOD. 2003;101(12):4930-4936
T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma
Hansson L; Rabbani H; Fagerberg J; Österborg A; Mellstedt K
Article: BLOOD. 2003;101(11):4607-4610
Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells
Rasmussen T; Hansson L; Österborg A; Johnsen HE; Mellstedt H
Article: LEUKEMIA. 2003;17(5):894-899
Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL
Kokhaei P; Rezvany MR; Virving L; Choudhury A; Rabbani H; Österborg A; Mellstedt H
Article: BLOOD. 2003;101(3):1063-1070
Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia
Rezvany MR; Jeddi-Tehrani M; Wigzell H; Österborg A; Mellstedt H
Article: HEMATOLOGY JOURNAL. 2003;4(4):248-252
Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.
Lundin J; Osterborg A; Björkholm M; Björkstrand B; Celsing F; Hjalmar V; Linder O; Luthman M; Merup M; Tidefelt U; Mellstedt H; Myeloma Group of Central Sweden
Article: DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION. 2003;112:61-67
Immunogenicity of GM-CSF products in cancer patients following immunostimulatory therapy with GM-CSF.
Wadhwa M; Mellstedt H; Small E; Thorpe R
Article: JOURNAL OF CLINICAL VIROLOGY. 2003;26(1):71-77
BK virus (BKV) quantification in urine samples of bone marrow transplanted patients is helpful for diagnosis of hemorrhagic cystitis, although wide individual variations exist
Priftakis P; Bogdanovic G; Kokhaei P; Mellstedt H; Dalianis T
Article: DRUGS OF TODAY. 2003;39:1-16
Monoclonal antibodies in human cancer
Mellstedt H
Article: BLOOD. 2002;100(3):768-773
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Österborg A
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2002;51(5):255-262
Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression
Skog ALH; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2002;51(4):209-218
Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma
Mosolits S; Steinitz M; Harmenberg U; Ruden U; Eriksson E; Mellstedt H; Fagerberg J
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2002;55(5):493-502
Spontaneous Downregulation of antibody/autoantibody synthesis in susceptible mice upon chronic exposure to mercuric chloride is not owing to a general immunosuppression
Roether S; Rabbani H; Mellstedt H; Abedi-Valugerdi M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2002;68(5):299-306
Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL)
Rossmann ED; Lewin N; Jeddi-Tehrani M; Österborg A; Mellstedt H
Article: HYBRIDOMA. 2002;21(2):99-101
MAb17-1A and Cytokines for the treatment of patients with colorectal carcinoma
Frödin JE; Fagerberg J; Skog ALH; Liljefors M; Ragnhammar P; Mellstedt H
Article: CANCER RESEARCH. 2002;62(5):1364-1369
Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen
Ullenhag GJ; Frödin JE; Strigård K; Mellstedt H; Magnusson CGM
Article: INTERNATIONAL JOURNAL OF CANCER. 2002;97(3):344-348
Significance of phosphotyrosine proteins, Bcl-2 and p53 for apoptosis in resting B-chronic lymphocytic leukemia (CLL) cells
Laytragoon-Lewin N; Rossmann ED; Castro J; Mellstedt H
Article: DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION. 2002;109:79-86
Experience measuring antibodies to both drug and impurities and their clinical sequelae.
Wadhwa M; Ragnhammar P; Mellstedt H; Gallo P; Thorpe R
Article: MEDICAL ONCOLOGY. 2002;19:S21-S26
Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia
Osterborg A; Mellstedt H; Keating M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;115(2):263-271
Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern
Rezvany MR; Jeddi-Tehrani M; Biberfeld P; Söderlund J; Mellstedt H; Österborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;113(4):1020-1034
Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.
Myeloma Trialists' Collaborative Group
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2001;66(5):342-346
Increased serum levels of soluble Fas in progressive B-CLL
Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Article: CLINICAL CANCER RESEARCH. 2001;7(5):1163-1170
Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2
Skog ALH; Wadhwa M; Hassan M; Gharizadeh B; Bird C; Ragnhammar P; Thorpe R; Mellstedt H
Article: CLINICAL IMMUNOLOGY. 2001;99(1):65-74
Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation
Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; Österborg A; Thorpe R; Mellstedt H; Wadhwa M
Article: HEMATOLOGY JOURNAL. 2001;2(5):300-306
Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies.
Rossmann ED; Lundin J; Lenkei R; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;112(1):155-160
Interleukin 4 therapy for patients with chronic lymphocytic leukaemia:: a phase I/II study
Lundin J; Kimby E; Bergmann L; Karakas T; Mellstedt H; Österborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(2):608-617
Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia
Rezvany MR; Jeddi-Tehrani M; Rabbani H; Lewin N; Avila-Cariño J; Österborg A; Wigzell H; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(1):230-238
Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia
Rezvany MR; Jeddi-Tehrani M; Rabbani H; Rudén U; Hammarström L; Österborg A; Wigzell H; Mellstedt H
Article: ANTICANCER RESEARCH. 2000;20(2B):1093-1100
Alteration of cellular mediated cytotoxicity, T cell receptor zeta (TcR ζ) and apoptosis related gene expression in nasopharyngeal carcinoma (NPC) patients:: Possible clinical relevance
Laytragoon-Lewin N; Porwit-Macdonald A; Mellstedt H; Lewin F
Article: ANNALS OF ONCOLOGY. 2000;11:191-194
Monoclonal antibodies as enhancers of the host's immunoresponse against the tumour
Mellstedt H
Article: MEDICAL ONCOLOGY. 1999;16(4):289-295
Cytokine expression in B-CLL in relation to disease progression and in vitro activation
Aguilar-Santelises M; Gigliotti D; Osorio LM; De Santiago A; Mellstedt H; Jondal M
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1999;48(8):463-470
Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma
Skog ALH; Ragnhammar P; Fagerberg J; Frödin JE; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Article: HUMAN GENE THERAPY. 1999;10(14):2325-2335
A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group.
Shand N; Weber F; Mariani L; Bernstein M; Gianella-Borradori A; Long Z; Sorensen AG; Barbier N
Article: CELLULAR IMMUNOLOGY. 1999;196(2):110-121
Induction of CD4⁺ and CD8⁺ Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides
Fagerberg J; Askelöf P; Wigzell H; Mellstedt H
Article: BLOOD. 1999;94(3):1063-1069
Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia:: Major perturbations are preferentially seen within the CD4 T-Cell subset
Rezvany MR; Jeddi-Tehrani M; Österborg A; Kimby E; Wigzell H; Mellstedt H
Article: EUROPEAN JOURNAL OF CANCER. 1999;35:S29-S32
Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man
Mellstedt H; Fagerberg J; Österborg A
Article: CLINICAL CANCER RESEARCH. 1999;5(6):1353-1361
Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF
Wadhwa M; Skog ALH; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;80(5):671-680
T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma
Fagerberg J; Yi Q; Gigliotti D; Harmenberg U; Rudén U; Persson B; Österborg A; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1999;47(6):315-320
Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma
Mosolits S; Harmenberg U; Rudén U; Öhman L; Nilsson B; Wahren B; Fagerberg J; Mellstedt H
Article: PATHOLOGIE ET BIOLOGIE. 1999;47(2):211-215
Active idiotype vaccination in multiple myeloma -: GM-CSF may be an important adjuvant cytokine
Mellstedt H; Österborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 1998;16(12):3832-3842
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1998;47(3):131-142
Pharmacological administration of granulocyte/macrophage-calony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen
Samanci A; Yi Q; Fagerberg J; Strigård K; Smith G; Rudén U; Wahren B; Mellstedt H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1998;61(4):266-271
Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells
Laytragoon-Lewin N; Duhony E; Bai XF; Mellstedt H
Article: JOURNAL OF CLINICAL ONCOLOGY. 1998;16(10):3257-3263
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas:: A phase II multicenter study
Lundin J; Österborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 1998;4(8):1921-1929
Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor
Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frodin JE; Biberfeld P; Mellstedt H
Article: INTERNATIONAL JOURNAL OF CANCER. 1998;76(6):909-912
Bcl-2 rearrangement detected by pulsed-field gel electrophoresis (PFGE) in B-chronic lymphocytic leukemia (CLL) cells
Laytragoon-Lewin N; Kashuba V; Mellstedt H; Klein G
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 1998;1(4):693-702
Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinical trials.
Zhao Q; Blomquist E; Bolander H; Gedda L; Hartvig P; Janson J; Lundqvist H; Mellstedt H; Nilsson S; Nistèr M; Sundin A; Tolmachev V; Westlin J; Carlsson J
Article: BLOOD. 1998;91(7):2459-2466
Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
Österborg A; Yi Q; Henriksson L; Fagerberg J; Bergenbrant S; Jeddi-Tehrani M; Rudén U; Lefvert AK; Holm G; Mellstedt H
Article: IMMUNOLOGY LETTERS. 1998;60(2-3):73-79
Recognition of B-CLL cells experimentally infected with EBV by autologous T lymphocytes
Tomita Y; Avila-Cariño J; Yamamoto K; Mellstedt H; Klein E
Article: INTERNATIONAL JOURNAL OF CANCER. 1997;73(6):790-794
Induction of a T- and B-cell response against a unique amino acid sequence of the mouse IgG(2A) hinge region in a MAb-treated patient
Wersall P; Fagerberg J; Ohlsson I; Ruden U; Boethius J; Mellstedt H
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1997;27(9):2245-2252
T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8(+) T cell expansions are found preferentially in patients with a low tumor burden
Halapi E; Werner A; Wahlstrom J; Osterborg A; JeddiTehrani M; Yi Q; Janson CH; Wigzell H; Grunewald J; Mellstedt H
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1997;234(2):296-299
Activities of vitamin Q(10) in animal models and a serious deficiency in patients with cancer
Folkers K; Osterborg A; Nylander M; Morita M; Mellstedt H
Article: INTERNATIONAL JOURNAL OF CANCER. 1997;71(3):345-349
Epstein-Barr virus (EBV) gene expression in lymphoid B cells during acute infectious mononucleosis (IM) and clonality of the directly growing cell lines
LaytragoonLewin N; Chen F; AvilaCarino J; Klein G; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1997;44(3):157-164
Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma
Wersall P; Ohlsson I; Biberfeld P; Collins VP; vonKrusenstjerna S; Larsson S; Mellstedt H; Boethius J
Article: BLOOD. 1997;89(8):2833-2841
CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM
Osorio LM; DeSantiago A; AguilarSantelises M; Mellstedt H; Jondal M
Article: JOURNAL OF MOLECULAR MEDICINE. 1997;75(4):300-304
Gene therapy for glioblestome multiforme: In vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
Stockhammer G; Brotchi J; Leblanc R; Bernstein M; Schackert G; Weber F; Ostertag C; Mulder NH; Mellstedt H; Seiler R; Yonekawa Y; Twerdy K; Kostron H; DeWitte O; Lambermont M; Velu T; Laneuville P; Villemure JG; Rutka JT; Warnke P; Laseur M; Mooij JJA; Boethius J; Mariani L; Meyer M; Brandli C; Frei K; Konu D; GianellaBorradori A
Article: JOURNAL OF CLINICAL ONCOLOGY. 1997;15(4):1567-1574
Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
Osterborg A; Dyer MJS; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H; Rankin E; Tsekouras C; Pangalis GA; Cavalli F; Sessa C; Huhn D; Marcus R; Maughan T; Poynton C; Nissen N; Carney D; Brittinger G; Uppenkamp M; Elonen E; Teerenhovi L; Engert; Willemze R; KluinNelemans J; Thomas J; Epenetos AA; Nethersell A; Dyer M; Catovsky D; Dicato M; Bastion Y; Coiffier B; Ranada JMF; Crowther D; Woll P; Raemakaers J; dePauw B; Degos L; Gissellbrecht; Reiffers J; Mellstedt H; Fassas A; Anagnostopoulos A; Bunjes D; Jaeger U; Stahel RA
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1997;96(2):338-345
Idiotype-specific T lymphocytes in monoclonal gammopathies: Evidence for the presence of CD4(+) and CD8(+) subsets
Yi Q; Eriksson I; He W; Holm G; Mellstedt H; Osterborg A
Article: INTERNATIONAL JOURNAL OF CANCER. 1997;70(1):1-8
B-CLL cells with unusual properties
AvilaCarino J; Lewin N; Tomita Y; Szeles A; Sandlund A; Mosolits S; Mellstedt H; Klein G; Klein E
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;58(1):5-13
Clonal CD8(+) and CD52(-) T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Article: IMMUNOLOGY LETTERS. 1996;54(1):45-52
B-CLL cells experimentally infected with EBV enter DNA synthesis, produce cytokines and stimulate T-lymphocytes
AvilaCarino J; Andersson J; Mellstedt H; Klein E
Article: JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY. 1996;44(7):767-776
Retrieval of leukocyte antigens in paraffin-embedded rat tissues
Shetye JD; Scheynius A; Mellstedt HT; Biberfeld P
Article: INTERNATIONAL JOURNAL OF CANCER. 1996;69(2):114-119
Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression
AguilarSantelises M; Rottenberg ME; Lewin N; Mellstedt H; Jondal M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;93(1):151-153
Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia
Osterborg A; Fassas AS; Anagnostopoulos A; Dyer MJS; Catovsky D; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1996;42(2):81-87
Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A
Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frodin JE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;92(4):840-846
Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients
Bergenbrant S; Yi Q; Osterborg A; Bjorkholm M; Osby E; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;92(2):393-400
Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease
Sjoberg J; AguilarSantelises M; Sjogren AM; Pisa EK; Ljungdahl A; Bjorkholm M; Jondal M; Mellstedt H; Pisa P
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;92(1):71-76
Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): Association with malignant transformation
Isaksson E; Bjorkholm M; Holm G; Johansson B; Nilsson B; Mellstedt H; Osterborg A
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;63(4):486-490
EPSTEIN-BARR-VIRUS (EBV)-CARRYING CELLS OF A CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) SUBPOPULATION EXPRESS EBNA1 AND LMPS BUT NOT EBNA2 IN-VIVO
LAYTRAGOONLEWIN N; CHEN F; AVILACARINO J; ZOU JZ; MELLSTEDT H; ERNBERG I; KLEIN G
Article: ANNALS OF ONCOLOGY. 1995;6(9):895-899
Fired versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease - A prospective randomized trial
Bjorkholm M; Axdorph U; Grimfors G; Merk K; Johansson B; Landgren O; Svedmyr E; Mellstedt H; Holm G
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1995;7(5):1049-1056
DIFFERENT DOSE REGIMENS OF THE MOUSE MONOCLONAL-ANTIBODY 17-1A FOR THERAPY OF PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA
RAGNHAMMAR P; FRODIN JE; HJELM AL; FAGERBERG J; WERSALL P; LINDEMALM C; NILSSON B; FOX K; MAGNUSSON I; EWERTH S; THOR K; SECHER E; MELLSTEDT H
Article: BLOOD. 1995;86(8):3043-3049
IDIOTYPE-REACTIVE T-CELL SUBSETS AND TUMOR LOAD IN MONOCLONAL GAMMOPATHIES
YI Q; OSTERBORG A; BERGENBRANT S; MELLSTEDT H; HOLM G; LEFVERT AK
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;63(2):190-192
RESPONSE TO INTERFERON THERAPY IN PATIENTS WITH MULTIPLE-MYELOMA CORRELATES WITH EXPRESSION OF THE BCL-2 ONCOPROTEIN
SANGFELT O; OSTERBORG A; GRANDER D; ANDERBRING E; OST A; MELLSTEDT H; EINHORN S
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;61(6):765-772
ALTERATIONS IN THE SIGNAL-TRANSDUCING MOLECULES OF T-CELLS AND NK CELLS IN COLORECTAL TUMOR-INFILTRATING, GUT MUCOSAL AND PERIPHERAL LYMPHOCYTES - CORRELATION WITH THE STAGE OF THE DISEASE
MATSUDA M; PETERSSON M; LENKEI R; TAUPIN JL; MAGNUSSON I; MELLSTEDT H; ANDERSON P; KIESSLING R
Article: MEDICAL ONCOLOGY. 1995;12(2):69-77
INCREASED LAK AND T-CELL ACTIVATION IN RESPONDING RENAL-CELL CARCINOMA PATIENTS AFTER LOW-DOSE CYCLOPHOSPHAMIDE, IL-2 AND ALPHA-IFN
WERSALL P; MELLSTEDT H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1995;40(6):367-375
GRANULOCYTE MACROPHAGE-COLONY-STIMULATING FACTOR AUGMENTS THE INDUCTION OF ANTIBODIES, ESPECIALLY ANTIIDIOTYPIC ANTIBODIES, TO THERAPEUTIC MONOCLONAL-ANTIBODIES
RAGNHAMMAR P; FAGERBERG J; FRODIN JE; WERSALL P; HANSSON LO; MELLSTEDT H
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1995;92(11):4773-4777
HUMAN ANTIIDIOTYPIC ANTIBODIES INDUCED A HUMORAL AND CELLULAR IMMUNE-RESPONSE AGAINST A COLORECTAL CARCINOMA-ASSOCIATED ANTIGEN IN PATIENTS
FAGERBERG J; STEINITZ M; WIGZELL H; ASKELOF P; MELLSTEDT H
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;61(2):159-164
DETECTION OF 2 EPSTEIN-BARR-VIRUS (EBV)-CARRYING LEUKEMIC-CELL CLONES IN A PATIENT WITH CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)
LEWIN N; AVILACARINO J; MINAROVITS J; LENNETTE E; BRAUTBAR C; MELLSTEDT H; KLEIN G; KLEIN E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1995;89(1):110-116
IDIOTYPE-SPECIFIC T-CELLS IN MULTIPLE-MYELOMA STAGE-I - AN EVALUATION BY 4 DIFFERENT FUNCTIONAL TESTS
OSTERBORG A; YI Q; BERGENBRANT S; HOLM G; LEFVERT AK; MELLSTEDT H
Article: CANCER BIOTHERAPY. 1995;10(1):5-12
SUBCUTANEOUS INTERLEUKIN-2 AND ALPHA-INTERFERON IN ADVANCE COLORECTAL-CARCINOMA - A PHASE-II STUDY
HJELM AL; RAGNHAMMAR P; FAGERBERG J; MAGNUSSON I; FRODIN JE; SVANSTROM R; SHETYE J; MELLSTEDT H; WERSALL JP
Visa fler

Alla övriga publikationer

Corrigendum: CLINICAL CANCER RESEARCH. 2019;25(9):2939
Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor (vol 10, pg 3273, 2004)
Ullenhag GJ; Frodin J-E; Jeddi-Tehrani M; Lidstromer N; Strigard K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
Meeting abstract: BLOOD. 2018;132:4421
Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatement in Relapsed or Refactory Chronic Lymphocytic Leukemia Patients
Palma M; Heimersson K; Mulder TA; Nasman-Glaser B; Osterborg A; Mellstedt H
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2018;182(4):590-594
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study
Winqvist M; Palma M; Heimersson K; Mellstedt H; OEsterborg A; Lundin J
Editorial comment: JOURNAL OF ONCOLOGY PRACTICE. 2017;13(9):15s-16s
European Perspective on Biosimilars
Mellstedt H
Corrigendum: LEUKEMIA RESEARCH. 2017;57:127
Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS) (Vol 13, 31, 1989)
Garcia C; Rosen A; Kimby E; Aguilar-Santelises M; Jondal M; Bjorkhilm M; Holm G; Mellstedt H
Review: TUMOR BIOLOGY. 2017;39(5):1010428317699797-101042831769979
Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin
Kast RE; Hill QA; Wion D; Mellstedt H; Focosi D; Karpel-Massler G; Heiland T; Halatsch M-E
Meeting abstract: ANNALS OF ONCOLOGY. 2016;27:vi530
First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor
Mellstedt H; Hojjat-Farsangi M; Daneshmanesh AH; Moshfegh A; Bystrom S; Norin M; Olin T; Schultz J; Vagberg J; Osterborg A
Review: JOURNAL OF DRUG TARGETING. 2016;24(5):373-385
Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
Kokhaei P; Jadidi-Niaragh F; Sotoodeh Jahromi A; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Meeting abstract: BLOOD. 2015;126(23):2912
First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Vagberg J; Styrbjorn B; Schultz J; Olsson E; Lofberg C; Norstrom C; Norin M; Olin T; Osterborg A; Mellstedt H
Review: CURRENT MEDICAL RESEARCH AND OPINION. 2015;31(12):2325-2330
Biosimilars - terms of use
Declerck P; Mellstedt H; Danese S
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2015;169(3):455-458
The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Khan AS; Mikaelsson E; Österborg A; Mellstedt H
Review: SEMINARS IN CANCER BIOLOGY. 2014;29:21-31
The receptor tyrosine kinase ROR1-An oncofetal antigen for targeted cancer therapy
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):4770
Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Mikaelsson E; Khan AS; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):3184
Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease region
Moshfegh A; Hogfeldt T; Jaing C; Lundahl J; Osterborg A; Loughlin KM; Gardner SN; Gharizadeh B; Porwit A; Bahnassy AA; Zekri A-RN; Khaled HM; Mellstedt H
Review: NATURE REVIEWS CLINICAL ONCOLOGY. 2014;11(9):509-524
Therapeutic vaccines for cancer: an overview of clinical trials
Melero I; Gaudemack G; Gerritsen W; Huber C; Parmiani G; Scholl S; Thatcher N; Wagstaff J; Zielinski C; Faulkner I; Mellstedt H
Letter: LAKARTIDNINGEN. 2014;111(22-23):1011
[Cheaper with biosimilars, but safety comes first].
Mellstedt H
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):e13561
A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1.
Mellstedt H; Daneshmanesh AH; Moshfegh A; Farsangl MH; Khan S; Mlkaelsson E; Vagberg J; Systrom S; Schultz J; Olin T; Ostorborg A
Meeting abstract: BLOOD. 2012;120(21):4583
Dishevelled Proteins of Wnt Signaling Pathways Are Highly Expressed in Chronic Lymphocytic Leukemia
Khan AS; Sandin A; Osterborg A; Hojjat-Farsangi M; Mellstedt H; Moshfegh A
Meeting abstract: BLOOD. 2012;120(21):1769
Monoclonal Antibody Against ROR1 in Chronic Lymphocytic Leukemia Cells Induced Apoptosis Via PI3-Kinase/AKT/CREB Pathway
Daneshmanesh AH; Hojjat-Farsangi M; Sandin A; Khan AS; Moshfegh A; Jeddi-Tehrani M; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2012;72:3027
Dishevelled proteins are highly upregulated in chronic lymphocytic leukemia
Khan AS; Osterborg A; Moshfegh A; Mellstedt H
Other: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2012;61(4):587-591
First International Meeting of the Thematic Centre for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC) 13-14 June 2011, Ljusterö, Sweden.
Choudhury A; Höglund P; Kiessling R; Kärre K; Lundqvist A; Malmberg K; Mellstedt H; Scheynius A; Winqvist O; Osterborg A
Review: CANCER TREATMENT REVIEWS. 2012;38(1):68-75
Epithelial cell adhesion molecule expression (CD326) in cancer: A short review
Patriarca C; Macchi RM; Marschner AK; Mellstedt H
Review: LAKARTIDNINGEN. 2011;108(42):2090-2094
[Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].
Mellstedt H; Gimsing P; Waage A
Review: LUNG CANCER. 2011;73(1):11-17
Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience
Mellstedt H; Vansteenkiste J; Thatcher N
Letter: BLOOD CANCER JOURNAL. 2011;1(6):e22
Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
Karlsson C; Dahl H; Lundin J; Rossmann E; Brytting M; Mellstedt H; Linde A; Osterborg A
Meeting abstract: CANCER RESEARCH. 2011;71:5011
Difference in expression of STAT3 and STAT5b in Swedish and Egyptian patients with activated b-cell subtype of diffuse large b-cell lymphoma
Jacobson T; Bahnassy AA; Lundahl J; Tamm KP; Porwit A; Zekri A-RN; Khaled HM; Mellstedt H; Moshfegh A
Editorial comment: FUTURE ONCOLOGY. 2010;6(7):1065-1067
Implications of the development of biosimilars for cancer treatment
Mellstedt H
Meeting abstract: CANCER RESEARCH. 2010;70:2171
Viral infection as an etiological risk factor for diffuse large B cell lymphoma (DLBCL): A comparative study between Egypt and Sweden
Jacobson TAS; Bahnassy AA; Moshfeg A; Zekri ARN; Porwit AP; Lundahl J; Mokhtar NM; Abdel-Hamid NA; Khaled HM; Mellstedt H
Meeting abstract: EJC SUPPLEMENTS. 2009;7(2):78
Biosimilars: issues facing clinicians
Mellstedt H
Review: LAKARTIDNINGEN. 2009;106(23):1563-1566
[Biosimilar products--cheaper version of biological drugs. New possibilities within several therapeutic fields].
Mellstedt H
Published conference paper: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2008;57(11):1705-1710
Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
Palma M; Adamson L; Hansson L; Kokhaei P; Rezvany R; Mellstedt H; Oesterborg A; Choudhury A
Published conference paper: ANNALS OF ONCOLOGY. 2008;19:vii241-vii247
Overcoming immunosuppressive mechanisms
Widen K; Mozaffari F; Choudhury A; Mellstedt H
Review: ANNALS OF ONCOLOGY. 2008;19(3):411-419
The challenge of biosimilars
Mellstedt H; Niederwieser D; Ludwig H
Editorial comment: ANNALS OF ONCOLOGY. 2007;18:1-2
Second European Breast Cancer meeting, 'Good risks and bad risks: Physicians' and patients' perspectives on adjuvant treatment for hormone-responsive early breat cancer', 20-21 May 2006, Stockholm, Sweden - Introduction
Mellstedt H
Meeting abstract: EJC SUPPLEMENTS. 2007;5(4):8
G-CSF biosimilars - approval process, substitution and extrapolation
Niederwiesser D; Ludwig H; Mellstedt H
Meeting abstract: EJC SUPPLEMENTS. 2007;5(4):7-8
Biosimilars in oncology and hematology - what should a physician know
Mellstedt H; Ludwig H; Niederwieser D
Editorial comment: ANNALS OF ONCOLOGY. 2007;18(6):969-970
National integration of European standards
Bajetta E; Gevorgyan A; Mellstedt H
Letter: LEUKEMIA. 2006;20(12):2204-2007
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia:: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation
Karlsson C; Norin S; Kimby E; Sander B; MacDonald AP; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Editorial comment: THE LANCET ONCOLOGY. 2006;7(9):700-701
Keynote comment: Deliberations of a born-again cancer immunotherapist
Mellstedt H
Published conference paper: ANNALS OF ONCOLOGY. 2006;17:X144-X154
The biology and treatment of chronic lymphocytic leukemia
Palma M; Kokhaei P; Lundin J; Choudhury A; Mellstedt H; Osterborg A
Editorial comment: JOURNAL OF CLINICAL ONCOLOGY. 2006;24(21):3497
Introduction: ASCO-ESMO Consensus Statement on Quality Cancer Care
Horning SJ; Mellstedt H
Editorial comment: ANNALS OF ONCOLOGY. 2006;17(7):1061
Introduction: ASCO-ESMO consensus statement on quality cancer care.
Horning SJ; Mellstedt H
Review: ANNALS OF ONCOLOGY. 2006;17 Suppl 8:viii24-viii31
Cancer initiatives in developing countries.
Mellstedt H
Editorial comment: ANNALS OF ONCOLOGY. 2006;17:viii7-viii8
Cancer in developing countries: challenges and solutions
Reeler AV; Mellstedt H
Review: SEMINARS IN ONCOLOGY. 2006;33(2):S29-S35
Strategies in the management of alemtuzumab-related side effects
Osterborg A; Karlsson C; Lundin J; Kimby E; Mellstedt H
Editorial comment: ANNALS OF ONCOLOGY. 2006;17:5
Welcome to TAT 2006!
Giaccone B; Lobbezoo M; Mellstedt H
Published conference paper: ANNALS OF ONCOLOGY. 2006;17:24-31
Cancer initiatives in developing countries
Mellstedt H
Review: ADVANCES IN CANCER RESEARCH. 2006;95:147-202
Clinical results of vaccine therapy for cancer: Learning from history for improving the future
Choudhury A; Mosolits S; Kokhaei P; Hansson L; Palma M; Mellstedt H
Editorial comment: ANNALS OF ONCOLOGY. 2005;16(9):1411-1412
ESMO at 30: mission ongoing.
Kosmidis PA; Ludwig H; Mellstedt H
Review: EXPERT REVIEW OF VACCINES. 2005;4(3):329-350
Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials
Mosolits S; Nilsson B; Mellstedt H
Review: ANNALS OF ONCOLOGY. 2005;16(6):847-862
Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results
Mosolits S; Ullenhag G; Mellstedt H
Published conference paper: ANNALS OF ONCOLOGY. 2005;16:ii113-ii123
Biology and treatment of chronic lymphocytic leukemia
Kokhaei P; Palma A; Mellstedt H; Choudhury A
Meeting abstract: BLOOD. 2004;104(11):419A
Long-term Id vaccination combined with IL-12 or IL-12 and GM-CSF in early stage multiple myeloma patients
Hansson L; Abdalla AO; Rabbani H; Osterborg A; Mellstedt H
Meeting abstract: BLOOD. 2004;104(11):277A
Virus reactivation profile as assessed by PCR and serology pattern following first-line alemtuzumab (anti-CD52 monoclonal antibody, Campath®) therapy in patients with B-CLL.
Karlsson C; Dahl H; Linde A; Lundin J; Björkholm M; Mellstedt H; Osterborg A
Meeting abstract: BLOOD. 2004;104(11):288B
Comparison of antigen-loading strategies for DC-based immunotherapy of B-CLL.
Mellstedt H; Kokhaei P; Osterborg A; Choudhury A
Meeting abstract: BLOOD. 2004;104(11):689A
T-cell function in patients with B-cell chronic lymphocytic leukemia (B-CLL) following alemtuzumab (Campath®) or fludarabine treatment.
Kiaii S; Mozaffari F; Lundin J; Rezvany R; Chudhury A; Mellstedt H; Osterborg A
Meeting abstract: BLOOD. 2004;104(11):54A
Downregulating the fibromodulin gene by short interfering RNA causes B-CLL cell death.
Choudhury A; Derkow K; Mikaelsson E; Kokhaei P; Österborg A; Rabbani H; Mellstedt H
Letter: LEUKEMIA. 2003;17(11):2252-2254
T-cell signaling and costimulatory molecules in B-chronic lymphocytic leukemia (B-CLL):: an increased abnormal expression by advancing stage
Rossmann ED; Jeddi-Tehrani M; Österborg A; Mellstedt H
Editorial comment: ANNALS OF ONCOLOGY. 2001;12(8):1037-1038
ESMO minimum clinical recommendations--the beginning of a process.
Published conference paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2000;910:254-261
Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma
Mellstedt H; Fagerberg J; Frödin JE; Hjelm-Skog AL; Liljefors M; Markovic K; Mosolits S; Ragnhammar P
Published conference paper: ACTA ONCOLOGICA. 2000;39(7):797-800
Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma
Österborg A; Henriksson L; Mellstedt H
Editorial comment: ACTA ONCOLOGICA. 2000;39(7):763-764
Progress in the understanding of the biology and the treatment of multiple myeloma - A cure might be around the corner
Mellstedt H
Review: CURRENT OPINION IN HEMATOLOGY. 1999;6(3):169-175
Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.
Mellstedt H; Fagerberg J; Frödin JE; Henriksson L; Hjelm-Skoog AL; Liljefors M; Ragnhammar P; Shetye J; Osterborg A
Review: SEMINARS IN IMMUNOPATHOLOGY. 1999;21(1):19-35
T cell receptor usage in malignant diseases
Halapi E; Jeddi-Tehrani M; Österborg A; Mellstedt H
Review: LAKARTIDNINGEN. 1998;95(13):1405-1410
[Vaccination against cancer soon a therapeutic possibility. B-cell tumors, colonic cancer and melanoma may be suitable for this treatment].
Mellstedt H; Fagerberg J; Osterborg A
Addendum: INTERNATIONAL JOURNAL OF CANCER. 1996;65(5):714-715
Epstein Barr virus (EBV)-carrying cells of a chronic lymphocytic leukemia (CLL) subpopulation express EBNA1 and LMPS but not EBNA2 in vivo.
Laytragoon-Lewin N; Chen F; Avila-Carino J; Zou JZ; Mellstedt H; Ernberg I; Klein G
Other: CANCER RESEARCH. 1995;55(9):1824-1827
TUMOR-REGRESSION IN MONOCLONAL ANTIBODY-TREATED PATIENTS CORRELATES WITH THE PRESENCE OF ANTI-IDIOTYPE-REACTIVE T-LYMPHOCYTES
FAGERBERG J; HJELM AL; RAGNHAMMAR P; FRODIN JE; WIGZELL H; MELLSTEDT H
Review: CANCER JOURNAL. 1995;8(4):181-184
ANTIIDIOTYPES AND CANCER
FAGERBERG J; MELLSTEDT H
Visa fler

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI